Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 12

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 12
---
 director, we also believe that each of our directors has demonstrated business acumen, integrity and an ability to exercise sound judgment, as well as a commitment of service to Sionna and our board of directors. Nominees for Election as Class I Directors The following table identifies our director nominees, and sets forth their principal occupation and business experience during the last five years and their ages as of April 15, 2025.

| Name                         |     | Positions and Offices 
 Held with Sionna      |     | Director 
 Since    |      |     | Age |    |
| Joshua Resnick, M.D., M.B.A. |     | Director              |     |          | 2019 |     |     | 50 |
| Bruce Booth, D.Phil.         |     | Director              |     |          | 2020 |     |     | 51 |
| Lucian Iancovici, M.D.       |     | Director              |     |          | 2019 |     |     | 43 |

**Joshua Resnick, M.D., M.B.A.has served as a member of our board of directors since December 2019. Dr. Resnick is a senior managing director at RA Capital Management, L.P., where he previously served as a Managing Director from October 2018 to March 2023. Dr. Resnick is also a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Dr. Resnick has served on the boards of directors of PepGen Inc. (NASDAQ: PEPG) since November 2020, Aerovate Therapeutics, Inc. (NASDAQ: AVTE) since August 2020, as well as from October 2018 to February 2020, and Vor Biopharma Inc. (NASDAQ: VOR) since February 2019. Dr. 8

Resnick received a B.A. in chemistry from Williams College, an M.D. from the University of Pennsylvania Perelman School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania. We believe Dr. Resnick’s biopharmaceutical industry and investor experience and medical background provides him with the appropriate set of skills to serve as a member of our board of directors.

Bruce Booth, D.Phil.has served as a member of our board of directors since June 2020. Dr. Booth joined Atlas Venture in 2005 and